A new clinical practice update outlines a stepwise approach to diagnosing and managing refractory constipation before ...

Advances in biomarker-driven and individualized approaches in neurology and psychiatry will require new frameworks for value ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...

The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer ...

Compass Therapeutics, Inc. is rated a Buy with strong cash position and strong data readout by the end of 1H 2026. Read more ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...

Segment 6 focuses on decision-making in second-line therapy for cGVHD, centering on the role of ruxolitinib. Dr. DeFilipp ...

Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...